What's Happening
NRx Pharmaceuticals announced in April 2026 that its FDA application for a preservative-free formulation of ketamine is advancing through the review process. The company signaled meaningful progress, suggesting the agency is actively evaluating the submission rather than letting it sit in queue. While a final approval date has not been confirmed, the development marks a notable milestone in the push to bring a cleaner, pharmaceutical-grade ketamine formulation to a broader clinical market.
The original news was reported by citybiz on April 22, 2026.
Why Preservative-Free Matters for Oral and Tablet Users
Most of the ketamine currently used in compounded oral formulations — whether tablets, troches, or sublingual solutions — is derived from bulk pharmaceutical-grade ketamine that may contain benzethonium chloride or other preservatives depending on the compounding pharmacy's source and process. These preservatives are generally considered safe at low doses, but they are not without controversy, particularly for patients using ketamine frequently or at higher doses over a long treatment course.
A dedicated, FDA-approved preservative-free ketamine formulation would represent a meaningful quality benchmark. For oral tablet users specifically, this matters in a few ways. Tablets designed for sublingual or buccal absorption — where the drug absorbs through mucous membranes before it reaches the GI tract — expose those tissues repeatedly to whatever additives are present in the formulation. A preservative-free option reduces cumulative mucosal exposure, which is relevant for patients on maintenance protocols who may be dosing multiple times per week.
Beyond the safety angle, an FDA-cleared preservative-free product could also give prescribers and pharmacists a more standardized starting point, potentially improving batch-to-batch consistency in compounded oral preparations downstream.
How This Fits Into the Broader Ketamine Landscape
It's worth contextualizing NRx's application within the current regulatory environment. The only FDA-approved ketamine-derived product on the market today is esketamine (Spravato), an intranasal S-enantiomer formulation from Johnson & Johnson that requires in-clinic administration under observation. Racemic ketamine — the full molecule used in infusions, compounded tablets, and troches — remains technically off-label for depression and mental health indications, even as it is widely prescribed.
NRx has been working toward a more formal regulatory pathway for racemic ketamine, and a preservative-free injectable or infusion-grade formulation would likely be used in clinical and hospital settings first. However, the ripple effects for oral ketamine are real. A successful FDA approval of any new ketamine formulation signals continued regulatory engagement with the molecule, which supports the broader argument that oral and at-home ketamine deserves its own pathway — not just compounding workarounds.
For patients currently using ketamine tablets or troches at home, this kind of regulatory activity also matters for long-term access. The more FDA-reviewed ketamine products exist on the market, the harder it becomes to argue that compounded oral formulations represent an unacceptable risk. It strengthens the evidence base and the regulatory precedent.
Tablets vs. Infusions vs. Troches: Where Does This Land?
Patients often ask how oral tablets compare with infusions or troches when it comes to formulation quality and safety. Infusions use pharmaceutical-grade ketamine in a controlled clinical setting, which provides the highest level of standardization — but at significant cost, time, and access barriers. Troches and tablets from compounding pharmacies sit in a middle ground: they offer the convenience of at-home use and generally lower per-session cost, but formulation variability across pharmacies is a real factor.
Preservative-free compounded tablets already exist through some pharmacies, but they are not universally available, and the terminology is not always consistent. An FDA-approved preservative-free benchmark product would give patients and clinicians a clearer quality reference point when evaluating their compounding pharmacy's formulation choices.
Key Takeaway for Oral Ketamine Patients
NRx's FDA review progress doesn't change your current treatment options today, but it's a positive signal for the long-term legitimacy and quality standardization of ketamine formulations across the board. If you're using compounded tablets or troches, ask your pharmacy whether their ketamine source is preservative-free — especially if you're on a frequent dosing schedule. The option may already be available to you.
What to Watch Next
The key milestone to track is whether NRx receives a PDUFA date — the formal FDA target date for a decision — which would give the market a concrete timeline. Any Complete Response Letter (CRL) from the FDA, or conversely an approval notice, would likely move quickly through the ketamine clinical community. Providers running at-home ketamine programs and telehealth platforms will be watching closely, as an FDA-approved preservative-free formulation could eventually inform new prescribing and compounding standards. We'll continue covering this story as it develops.
Share